Peter Neumann
@PeterNeumann11
Followers
3K
Following
6K
Media
646
Statuses
3K
Director, @TuftsCEVR. Co-author, #therightpricebook.
Tufts Medical Center, Boston
Joined June 2012
Everyone wants lower drug prices, but the critical question is not how to cut prices, but how to align prices with the value delivered. Our new book explains how. Available at Oxford Univ Press ( https://t.co/fXLosiPk32) and Amazon ( https://t.co/Ql7FoiI4Nj).
5
13
67
Our new @HealthAffairs Forefront commentary asks whether #Medicare's IPAY 2027 negotiated drug prices reflect value for money. https://t.co/uDOxJySgGq
healthaffairs.org
Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.
0
0
1
The best books I read in 2024. My annual list. https://t.co/dPw4X0RgkX
@TuftsCEVR @peterbachmd @DusetzinaS @jonathaneig #books #BooksWorthReading
3
1
10
The outlook for US payer coverage of specialty drugs in 2005. Register here for our webinar, Dec 4, 3-3:30 ET: https://t.co/td7omRloxz
@jchambers241 @mollytoba @npcnow @brianreid #heor #biosimilars @TuftsCEVR
0
4
9
A cost-effective treatment for #Alzheimers would improve US population health and health equity. Read the new distributional CEA by CEVR and @genentech for data-driven insights on policies to further mitigate disparities. https://t.co/s1BW8CCSKv
jamanetwork.com
This economic evaluation estimates the health equity impact of a hypothetical disease-modifying treatment for early Alzheimer disease (AD) in the US and examines policies designed to mitigate health...
0
2
9
Small molecules and biologics are eligible for #IRA price negotiation 9 vs 13 years after approval. New CEVR research shows small molecules give similar health benefits at lower cost than biologics. Should IRA be reformed to set equivalent timelines? https://t.co/V42ZxYlA1g
healthaffairs.org
The Inflation Reduction Act of 2022 requires that Medicare negotiate a Maximum Fair Price for selected small-molecule drugs nine years after their Food and Drug Administration (FDA) approval and...
1
1
3
Me presenting @socmdm ! So happy to work with @ashleyleech @ddkim62 @PeterNeumann11 🙌 It was wonderful to share our findings on CEA thresholds in cost-per-QALY studies worldwide based on @TuftsCEVR CEA registry at #SMDM24
0
3
14
Thank you, @KathrynP_phd !
So fun to be in Boston w/ #CEA leaders @TuftsCEVR @PeterNeumann11 & so many other leaders that I can't name them all. Wow look at the growth of CEAs! When I started in field were almost none & now there are thousands!
0
1
1
Excited to have #SMDM24 meeting in Boston this year! Amber Barnato and @JagChhatwal kicking things off. @socmdm @TuftsCEVR
0
1
14
I’ll also be presenting at the Cost-Effectiveness Thresholds Used in Cost-Per-QALY Studies on Tuesday at 3:50PM — Don’t miss it! 🙌 Grateful for the support from @ashleyleech @ddkim62 @PeterNeumann11 #SMDM24 #MDMTwitter
0
4
9
✨💡Illuminators of cost-effectiveness analysis in health and medicine 💡✨ So inspired by the pioneers of #CEA who've shaped our field of study! @TuftsCEVR @PeterNeumann11 @AnkurFactorial @PSynnott29 #CelebrateCEA
0
1
14
Which #HEOR superhero are you? Looking forward to meeting many of my HEOR heroes at tomorrow’s symposium on cost-effectiveness analysis #CelebrateCEA @TuftsCEVR
0
3
11
Drug value assessments are important, but economists shouldn't neglect assessment of health services and procedures. Hear perspectives from CEVR's @PeterNeumann11, @RxEconomics, and EBRI's @pfronstin during Oct. 31 public webinar. Register now: https://t.co/hfMr9EP4GJ
0
5
8
The final agenda for the 10/26 symposium in Boston, "Celebrating CEA," is now available. Panelists include: @Basucally, @contirena1, Emond, Garrison, Lakdawalla, Phelps, Weinstein, etc. Register in person or online: https://t.co/XaDi6ztmB0
@TuftsCEVR @DukeMargolis @socmdm
0
9
18
Excited to announce that Milton Weinstein will join the "legends" panel at the 10/26 @TuftsCEVR-@DukeMargolis hosted symposium in Boston, "Celebrating Cost-Effectiveness Analysis." Moderated by @AnkurFactorial Register in person or online: https://t.co/OoD6YNXZzI
@socmdm
1
5
20
We are thrilled to announce that pioneering #CEA researcher Milton C. Weinstein has joined Panel 2 at the 10/26 Tufts-CEVR / Duke Margolis symposium. Register now! In person: https://t.co/X09ZYozhFR Webinar: https://t.co/WsaGPFDEVY
The 2nd panel at 10/26 Tufts-CEVR / Duke Margolis symposium will feature reflections on CEA from three luminaries: @AnkurFactorial, Marthe Gold, and Charles Phelps. Register now: In Person: https://t.co/L5gA6C35ch Webinar: https://t.co/WsaGPFDEVY
0
5
9
What does the future hold for CEA? Hear from experts @WrightCensored, @feralaes, @nlcrossnohere, and David Kim during Panel 5 at 10/26 Tufts-CEVR / Duke Margolis event. Register now: In-person: https://t.co/X09ZYozhFR Webinar: https://t.co/WsaGPFDEVY
0
4
4
I am super-pumped at the prospect of collaborating with Peter and his team. We're living in a time of value, and I can't wait to contribute to the conversation.
We are pleased to announce that @brianreid, a nationally-recognized expert in prescription drug policy and communications, has joined @TuftsCEVR as a Senior Fellow. More here: https://t.co/FX9nLdwHUg
#heor
3
2
18
We are pleased to announce that @brianreid, a nationally-recognized expert in prescription drug policy and communications, has joined @TuftsCEVR as a Senior Fellow. More here: https://t.co/FX9nLdwHUg
#heor
0
3
15
Join us in Las Vegas for #AMCPNexus 2024 for 2 educational sessions by @jchambers241 and @mollytoba's presentation of Fariel LaMountain's Platinum Ribbon-winning research on adalimumab product coverage. A full list of CEVR participation can be found here: https://t.co/U0dCpZdMn3
0
4
4